Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dina Visca

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Journal of Personalized Medicine|February 25, 2025
Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to OmalizumabDiego Bagnasco, Benedetta Bondi, Luisa Brussino, et al.
Respirology (Carlton, Vic.)|December 18, 2020
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progressionCarmel J W Stock, Rachel K Hoyles, Cecile Daccord, et al.
The European Respiratory Journal|April 18, 2020
Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impactMartina Bonifazi, Nicola Sverzellati, Eva Negri, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 8, 2020
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis NetworkGiovanni Battista Migliori, Simon Tiberi, Alimuddin Zumla, et al.
Biomedicines|February 24, 2024
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life PerspectiveMarco Caminati, Matteo Maule, Roberto Benoni, et al.
Respiratory Medicine|June 13, 2025
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-upLaura Pini, Marco Caminati, Matteo Maule, et al.
Journal of Clinical Medicine|May 25, 2024
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life StudyLaura Pini, Diego Bagnasco, Bianca Beghè, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2025
Profiling Blood Hypereosinophilia in Patients on Dupilumab Treatment for Respiratory Conditions: A Real-Life SnapshotMarco Caminati, Matteo Maule, Diego Bagnasco, et al.
Frontiers in Medicine|November 16, 2020
Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid)Bahaa Abu-Raya, Giovanni Battista Migliori, Miguel O'Ryan, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Clinical Rheumatology|January 10, 2020
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung diseaseCarmel J W Stock, Angelo De Lauretis, Dina Visca, et al.
Journal of Personalized Medicine|February 25, 2025
Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to OmalizumabDiego Bagnasco, Benedetta Bondi, Luisa Brussino, et al.
Respirology (Carlton, Vic.)|December 18, 2020
Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progressionCarmel J W Stock, Rachel K Hoyles, Cecile Daccord, et al.
The European Respiratory Journal|April 18, 2020
Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impactMartina Bonifazi, Nicola Sverzellati, Eva Negri, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 8, 2020
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis NetworkGiovanni Battista Migliori, Simon Tiberi, Alimuddin Zumla, et al.
Biomedicines|February 24, 2024
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life PerspectiveMarco Caminati, Matteo Maule, Roberto Benoni, et al.
Respiratory Medicine|June 13, 2025
ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-upLaura Pini, Marco Caminati, Matteo Maule, et al.
Journal of Clinical Medicine|May 25, 2024
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life StudyLaura Pini, Diego Bagnasco, Bianca Beghè, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2025
Profiling Blood Hypereosinophilia in Patients on Dupilumab Treatment for Respiratory Conditions: A Real-Life SnapshotMarco Caminati, Matteo Maule, Diego Bagnasco, et al.
Frontiers in Medicine|November 16, 2020
Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid)Bahaa Abu-Raya, Giovanni Battista Migliori, Miguel O'Ryan, et al.
Pageof 11